Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Current Assets (2024 - 2026)

Maze Therapeutics' Current Assets history spans 3 years, with the latest figure at $379.8 million for Q1 2026.

  • On a quarterly basis, Current Assets rose 26.72% to $379.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was $379.8 million, a 26.72% increase, with the full-year FY2025 number at $349.7 million, up 73.41% from a year prior.
  • Current Assets hit $379.8 million in Q1 2026 for Maze Therapeutics, up from $349.7 million in the prior quarter.
  • Over the last five years, Current Assets for MAZE hit a ceiling of $391.3 million in Q3 2025 and a floor of $201.7 million in Q4 2024.
  • Historically, Current Assets has averaged $315.6 million across 3 years, with a median of $324.7 million in 2025.
  • Biggest five-year swings in Current Assets: surged 73.41% in 2025 and later increased 26.72% in 2026.
  • Tracing MAZE's Current Assets over 3 years: stood at $201.7 million in 2024, then surged by 73.41% to $349.7 million in 2025, then increased by 8.6% to $379.8 million in 2026.
  • Business Quant data shows Current Assets for MAZE at $379.8 million in Q1 2026, $349.7 million in Q4 2025, and $391.3 million in Q3 2025.